估算每日抗生素危害:一项伞状综述及个体研究荟萃分析
该伞状综述纳入35篇系统综述、71项随机对照试验,评估成人及儿童患者较短与较长固定疗程(3至14天)抗生素治疗的危害。每延长一天抗生素治疗,不良事件发生比值增加4%(OR 1.04,95%CI 1.02-1.07),严重不良反应日比值亦增加(OR 1.09,95%CI 1.00-1.19);超感染与耐药日比值分别为OR 0.98(0.92-1.06)和OR 1.03(0.98-1.07)。
要点
- 每延长一天抗生素治疗,不良事件发生比值增加4%(OR 1.04,95%CI 1.02-1.07)。
- 严重不良反应的每日比值亦增加(OR 1.09,95%CI 1.00-1.19)。
- 超感染与耐药每日比值分别为OR 0.98(0.92-1.06)和OR 1.03(0.98-1.07)。
核心结论
- 每额外增加一天抗生素治疗与可测量的抗生素危害相关,尤其是不良事件。
- 这些数据可为临床医生权衡延长抗生素治疗的获益与风险提供额外参考。
研究设计与样本
- 伞状综述:检索三大数据库2000年至2020年7月30日任何语言的系统综述。
- 纳入评估固定疗程3至14天较短与较长抗生素治疗比较的系统综述。
- 从系统综述中识别用于荟萃分析的随机对照试验,纳入成人及儿童患者。
- 共纳入35篇系统综述,涵盖71项符合条件的随机对照试验。
- 采用随机效应荟萃分析估算并合并抗生素危害的每日比值比(OR)。
主要发现
- 研究最常评估呼吸道感染(n=36,51%)和尿路感染(n=29,41%)的治疗疗程。
- 共23 174例患者评估抗生素相关危害。
- 不良事件评估于20 345例患者,其中19.9%(n=4039)发生不良事件。
- 超感染评估于5776例患者,其中4.8%(n=280)发生超感染。
- 抗菌药物耐药评估于2330例患者,其中10.6%(n=246)发生耐药。
临床怎么用
- 原文结论指出这些数据可为临床医生权衡延长抗生素治疗的获益与风险提供额外参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is growing evidence supporting the efficacy of shorter courses of antibiotic therapy for common infections. However, the risks of prolonged antibiotic duration are underappreciated. OBJECTIVES: To estimate the incremental daily risk of antibiotic-associated harms. METHODS: We searched three major databases to retrieve systematic reviews from 2000 to 30 July 2020 in any language. ELIGIBILITY: Systematic reviews were required to evaluate shorter versus longer antibiotic therapy with fixed durations between 3 and 14 days. Randomized controlled trials included for meta-analysis were identified from the systematic reviews. PARTICIPANTS: Adult and paediatric patients from any setting. INTERVENTIONS: Primary outcomes were the proportion of patients experiencing adverse drug events, superinfections and antimicrobial resistance. RISK OF BIAS ASSESSMENT: Each randomized controlled trial was evaluated for quality by extracting the assessment reported by each systematic review. DATA SYNTHESIS: The daily odds ratio (OR) of antibiotic harm was estimated and pooled using random effects meta-analysis. RESULTS: Thirty-five systematic reviews encompassing 71 eligible randomized controlled trials were included. Studies most commonly evaluated duration of therapy for respiratory tract (n = 36, 51%) and urinary tract (n = 29, 41%) infections. Overall, 23 174 patients were evaluated for antibiotic-associated harms. Adverse events (n = 20 345), superinfections (n = 5776) and antimicrobial resistance (n = 2330) were identified in 19.9% (n = 4039), 4.8% (n = 280) and 10.6% (n = 246) of patients, respectively. Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event (OR 1.04, 95% CI 1.02-1.07). Daily odds of severe adverse effects also increased (OR 1.09, 95% CI 1.00-1.19). The daily incremental odds of superinfection and antimicrobial resistance were OR 0.98 (0.92-1.06) and OR 1.03 (0.98-1.07), respectively. CONCLUSION: Each additional day of antibiotic therapy is associated with measurable antibiotic harm, particularly adverse events. These data may provide additional context for clinicians when weighing benefits versus risks of prolonged antibiotic therapy.
引用
- Curran J, Lo J, Leung V, et al. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect. 2021. PMID: 34775072. doi:10.1016/j.cmi.2021.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。